Marta Perachino
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
Marta Perachino
Jul 20, 2024, 12:56 |
Blog
Marta Perachino: Highest level science
Matteo Lambertini shared a post by Marta Perachino, Research fellow at Vall d’Hebron Institute of Oncology, on…
Jun 19, 2024, 06:40 |
Blog
Matteo Lambertini: Let’s help each others to design important academic trials
Matteo Lambertini shared on X/Twitter: "So exciting and grateful to be back at EORTC, ESMO,…
Jun 18, 2024, 04:01 |
Blog
Matteo Lambertini: Great slide to explain type I and type II errors
Matteo Lambertini recently shared a post on X: "What a great slide to explain type…
May 17, 2024, 16:02 |
Blog
Marta Perachino: Check out our systematic review and metanalysis of ADCs vs TPC for mBC
Marta Perachino, Research fellow at Vall d’Hebron Institute of Oncology, shared a post on X: "For…
Mar 22, 2024, 06:12 |
Drugs
Paolo Tarantino: We’re running SATEEN, the first trial of sacituzumab govitecan + trastuzumab in patients with HER2 + MBC
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post by Marta…
All:
5
Posts:
1 - 100
Making Personal Experience a Political Priority: Insights from EU Commissioner Stella Kyriakides
Zolbetuximab is now approved by the US FDA
Highlights from NFCR’s GSAC24
SIOP Honoured Hansjörg Riehm with the 2024 Lifetime Achievement Award
Margaret Foti has received the 2024 Beacon Award for Women Leaders in Oncology
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube